Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients (2022)
Pietrobon, Anna Julia 
; Andrejew, Roberta ; Custodio, Ricardo Wesley Alberca ; Oliveira, Luana de Mendonça ; Scholl, Juliete Nathali ; Teixeira, Franciane Mouradian Emidio ; Brito, Cyro Alves de ; Glaser, Talita ; Kazmierski, Julia ; Goffinet, Christine ; Turdo, Anna Claudia; Yendo, Tatiana Mina ; Aoki, Valeria; Figueiró, Fabrício; Battastini, Ana Maria ; Ulrich, Henning ; Benard, Gil ; Duarte, Alberto José da Silva; Sato, Maria Notomi
Source: Frontiers in Immunology. Unidades: FM, IQ, ICB
Subjects: COVID-19, PURINAS, ADENOSINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIETROBON, Anna Julia et al. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Frontiers in Immunology, v. 13, p. 1-12 art. 1012027, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.1012027. Acesso em: 01 nov. 2024.APA
Pietrobon, A. J., Andrejew, R., Custodio, R. W. A., Oliveira, L. de M., Scholl, J. N., Teixeira, F. M. E., et al. (2022). Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. Frontiers in Immunology, 13, 1-12 art. 1012027. doi:10.3389/fimmu.2022.1012027NLM
Pietrobon AJ, Andrejew R, Custodio RWA, Oliveira L de M, Scholl JN, Teixeira FME, Brito CA de, Glaser T, Kazmierski J, Goffinet C, Turdo AC, Yendo TM, Aoki V, Figueiró F, Battastini AM, Ulrich H, Benard G, Duarte AJ da S, Sato MN. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients [Internet]. Frontiers in Immunology. 2022 ; 13 1-12 art. 1012027.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fimmu.2022.1012027Vancouver
Pietrobon AJ, Andrejew R, Custodio RWA, Oliveira L de M, Scholl JN, Teixeira FME, Brito CA de, Glaser T, Kazmierski J, Goffinet C, Turdo AC, Yendo TM, Aoki V, Figueiró F, Battastini AM, Ulrich H, Benard G, Duarte AJ da S, Sato MN. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients [Internet]. Frontiers in Immunology. 2022 ; 13 1-12 art. 1012027.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fimmu.2022.1012027
